Список проголосовавших за комментарий "<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Aurinia Pharma (<strong>AUPH </strong>+33.83%) announces 24-week data in all 10 patients from the AURION study; '70% (7/10) patients achieved complete remission at 24 weeks'</li><li>PhotoMedex (<strong>PHMD </strong>+26.96%) to sell its consumer products business to ICTV Brands for $9.5 mln</li><li>RedHill Biopharma (<strong>RDHL </strong>+4.58%) rovides progress update on RHB-104 phase III Crohn's disease program and introduces option for early stop for success in Q2/2017</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Alnylam Pharma (<strong>ALNY </strong>-45.99%) to discontinue Revusiran development, says decision does not impact Patisiran or any other RNAi therapeutic program in development</li><li>Provectus Pharma (<strong>PVCT </strong>-18.78%) files registration statement for a rights offering to its existing stockholders</li><li>Alphatec (<strong>ATEC </strong>-11.32%) reduced its workforce by approximately 20%; CFO Michael O'Neill resigned effective October 5</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>Alliqua (<strong>ALQA </strong>+3.31%) preannounces Q3 revenue just above/in-line with consensus</li><li>ICU Medical (<strong>ICUI </strong>+13.34%) to acquire the Hospira Infusion Systems biz from Pfizer (PFE) for $1 bln in cash & stock; reports Q3 prelim results & updates FY16 guidance</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Vanda Pharma (<strong>VNDA </strong>+3.38%) resumed with a Buy at Jefferies</li><li>Aerie Pharma (<strong>AERI </strong>+3.31%) target raised to $55 at Stifel — Analyst Day highlights best-in-class profile for rhopressa/roclatan and market enthusiasm</li><li>Quality Systems (<strong>QSII </strong>-6.23%) initiated with Sell ratings at UBS</li><li>Smith & Nephew (<strong>SNN </strong>-3.11%) downgraded to Hold from Buy at Berenberg</li><li>Intersect ENT (<strong>XENT </strong>-2.89%) initiated with a Hold at Deutsche Bank</li></ul>"